

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

Phospho-c-Raf (Ser259) Antibody

RRID:AB_330759

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9421, RRID:AB_330759

Antibody Information

URL: http://antibodyregistry.org/AB_330759

Proper Citation: Cell Signaling Technology Cat# 9421, RRID:AB_330759

Target Antigen: Phospho-c-Raf (Ser259)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10078658, AB_10836482, AB_330759.

Antibody Name: Phospho-c-Raf (Ser259) Antibody

Description: This polyclonal targets Phospho-c-Raf (Ser259)

Target Organism: rat, xenopusamphibian, h, m, mouse, r, x, human

Antibody ID: AB_330759

Vendor: Cell Signaling Technology

Catalog Number: 9421

Record Creation Time: 20250820T003627+0000

Record Last Update: 20250820T084326+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-c-Raf (Ser259) Antibody.

No alerts have been found for Phospho-c-Raf (Ser259) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bajikar SS, et al. (2024) Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. Human molecular genetics.

Wang Y, et al. (2023) Repositioning Lomitapide to block ZDHHC5-dependant palmitoylation on SSTR5 leads to anti-proliferation effect in preclinical pancreatic cancer models. Cell death discovery, 9(1), 60.

Qian F, et al. (2023) Activation of GPR44 decreases severity of myeloid leukemia via specific targeting of leukemia initiating stem cells. Cell reports, 42(7), 112794.

Zhang K, et al. (2023) Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF- κ B pathways. Military Medical Research, 10(1), 56.

Wong S, et al. (2023) RAF1 deficiency causes a lethal syndrome that underscores RTK signaling during embryogenesis. EMBO molecular medicine, 15(5), e17078.

Xia Y, et al. (2023) Repositioning of Montelukast to inhibit proliferation of mutated KRAS pancreatic cancer through a novel mechanism that interfere the binding between KRAS and GTP/GDP. European journal of pharmacology, 961, 176157.

Gao X, et al. (2022) Lyso-PAF, a biologically inactive phospholipid, contributes to RAF1 activation. Molecular cell, 82(11), 1992.

Joshi S, et al. (2021) Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. Communications biology, 4(1), 1333.

Liao S, et al. (2019) Tanshinol borneol ester, a novel synthetic small molecule angiogenesis stimulator inspired by botanical formulations for angina pectoris. British journal of pharmacology, 176(17), 3143.

Lian X, et al. (2019) The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease. British journal of pharmacology, 176(5), 711.

Sulahian R, et al. (2019) Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell reports, 29(1), 118.